Steven L. Warner

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

High-Throughput Virtual Screening Identifies Novel <i>N</i>′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors

Venkataswamy Sorna, Emily R. Theisen, Bret J. Stephens et al. · Journal of Medicinal Chemistry · 2013 · 205 citations · Full text

Drug Target, Hit Identification, Histone Lysine Methylation +21

S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor <i>In vivo</i> and Can Reduce Tumor Growth

Jody C. Chuang, Steven L. Warner, David Vollmer et al. · Molecular Cancer Therapeutics · 2010 · 151 citations · Full text

Targeting Aurora-2 kinase in cancer.

Steven L. Warner, David J. Bearss, Haiyong Han et al. · PubMed · 2003 · 116 citations

Cancer Research, Chromatin, Cell Regulation +14

Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells

Steven L. Warner, Bret J. Stephens, Stanley Nwokenkwo et al. · Clinical Cancer Research · 2009 · 110 citations · Full text